Flowvium
Back to Explorer

Moderna, Inc.

MRNAintermediary

Moderna pioneered commercial mRNA technology with its COVID-19 vaccine and is now building a multi-product mRNA platform spanning infectious disease, oncology, and rare genetic disorders. Its RSV vaccine approval and cancer-vaccine pipeline represent the next phase of mRNA's therapeutic potential.

Share:
⇄ Compare

Products & Revenue

Product Revenue Share

Revenue Breakdown ($8.8B)

Static data (loading live financials…)

COVID-19 Vaccines (62%)
RSV Vaccine (20%)
Grants & Collaborations (10%)
Other Pipeline Products (8%)

Segment Breakdown & Key Customers

Product Details

Spikevax (COVID-19 Vaccine)50%

mRNA-based COVID-19 vaccine and updated boosters

mRNA-1345 (RSV Vaccine)18%

mRNA respiratory syncytial virus vaccine

Flu/COVID Combo Vaccine5%

Combined influenza and COVID mRNA vaccine in late-stage trials

Oncology mRNA (INT-0167)3%

Individualized neoantigen mRNA cancer vaccines

Rare Disease Pipeline4%

mRNA therapeutics for genetic disorders (PA, MMA)

Supply Chain Relationships

Competitors

Pfizer Inc.

mRNA vaccines

Impact: Primary vaccine competitor

Regeneron Pharmaceuticals

Oncology immunotherapy

Impact: Competing in cancer vaccines

Partners

Eli Lilly and Company

Potential mRNA oncology collaboration

Impact: Exploratory

Macro & Market Context

제약 / 바이오Sector News

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Upcoming Catalysts

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Supply Chain Issues

★ 기회mRNA-4157 암백신 FDA 우선심사 신청
2026-04

Merck와 공동 개발 mRNA-4157/V940 흑색종 보조요법 BLA 제출 예정. 우선심사 적용 시 2026H2 승인 가능.

⚡ 리스크RSV 백신 경쟁 심화 — 매출 전망 하향
2026-03

Pfizer·GSK RSV 백신 시장 공유로 MRNA RSV 점유율 17%에 그침. 2026 RSV 매출 가이던스 하향 조정.

Institutional Signals

InstitutionActionValueQuarterFiling Date
BlackRockaccumulating$83M2024.062024-08-13↑
BlackRockreducing$28M2024.062024-08-13↓
BlackRockaccumulating$42M2024.062024-08-13↑
BlackRockreducing$2M2024.062024-08-13↓
BlackRockreducing$6M2024.062024-08-13↓
BlackRockaccumulating$59M2024.062024-08-13↑
BlackRockaccumulating$69M2024.062024-08-13↑
BlackRockaccumulating$1.2B2024.062024-08-13↑
BlackRockaccumulating$832M2024.062024-08-13↑
BlackRockaccumulating$47M2024.062024-08-13↑
BlackRockaccumulating$70M2024.062024-08-13↑
BlackRockaccumulating$40M2024.062024-08-13↑
BlackRockaccumulating$81M2024.062024-08-13↑
BlackRockreducing$69K2024.062024-08-13↓
BlackRockaccumulating$335M2024.062024-08-13↑
BlackRockreducing$9M2024.062024-08-13↓
BlackRockreducing$14M2024.062024-08-13↓
BlackRockaccumulating$60M2024.062024-08-13↑
BlackRockreducing$8M2024.062024-08-13↓
BlackRockreducing$2M2024.062024-08-13↓
BlackRockreducing$65K2024.062024-08-13↓
BlackRockaccumulating$46M2024.062024-08-13↑
Vanguard Groupaccumulating$57M2025.122026-01-29↑
Vanguard Groupaccumulating$9M2025.122026-01-29↑
Vanguard Groupaccumulating$3K2025.122026-01-29↑
Vanguard Groupaccumulating$21M2025.122026-01-29↑
Vanguard Groupaccumulating$2M2025.122026-01-29↑
Vanguard Groupaccumulating$1.1B2025.122026-01-29↑
State Streetreducing$483M2025.122026-02-13↓
Wellington Managementreducing$2M2025.122026-02-17↓
FMR (Fidelity)accumulating$641M2025.122026-02-17↑
FMR (Fidelity)accumulating$147M2025.122026-02-17↑
FMR (Fidelity)accumulating$737K2025.122026-02-17↑
FMR (Fidelity)accumulating$39M2025.122026-02-17↑

Institutional Ownership

13F basis · Q4 2025
InstitutionChangeOwnership %Prev. QuarterSharesValueSEC
Baillie GiffordIncreased8.20%—31.1M shares$1,400M13F
FidelityIncreased5.30%—20.0M shares$900M13F
WellingtonNew Position4.60%—17.3M shares$780M13F
ARK InvestMaintained2.50%—9.3M shares$420M13F
Total tracked ownership: 20.60%Total value: $3,500MBased on SEC EDGAR 13F-HR · 45-day reporting delay

Latest News

Loading news...

AI Analysis

Click "Get AI Analysis" for an AI-powered supply chain analysis of Moderna, Inc..

Company Info

Headquarters

Cambridge, Massachusetts, USA

Founded

2010

Employees

6,000+

News Gap Score

Gap Score72
Low GapHigh Gap

IB Activity

80

Media Score

30

Cascade Position

Role in Cascade

late mover

Typical Delay

2-5 trading days

Moderna benefits from broader biopharma innovation sentiment but has no direct GLP-1 program; moves are sentiment-driven.

View Full Cascade

Sector Overview — 제약 / 바이오

Sector News

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Key Themes

  • •Mounjaro/Wegovy — 비만·당뇨 넘어 심혈관·신장·NASH 적응증 확대
  • •Moderna mRNA-4157 암백신 — 흑색종 49% 재발 감소 (NEJM)
  • •REGN dupilumab 다적응증 확대 → 10조+ 매출 가시성

Upcoming Catalysts

  • ◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)
  • ◆MRNA 암백신 FDA BLA 제출 예정